Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASPAR: Enzalutamide and Rucaparib in First-Line Metastatic Castration-Resistant Prostate Cancer
NCT04455750Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cancer and Leukemia Group B. Started Oct 2021; status: active, not recruiting.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04455750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455750.